Re-posted, read down below
oanranger Member Level
Re-posted, read down below
oanranger Member Level Thursday, 05/25/17 05:32:13 PM
Re: oilywankanobe post# 44459
Post #
44489
of 44491 Go
"For the record Berman does take stock, it's hidden in the filings under BOD compensation. The commons need to understand Berman get $1,500.00 per week which is nothing until you take into account he receives them @ Par value which is .001"
It's very well hidden...I can't find it.
He and the other Directors have not reported changes in their holdings from year end to year end for a while. If they receive shares as your post implies they would have to have been flipping an equal number of shares within the year that the new shares were received.
There is no record of such issuances in the Statements of Shareholders Equity which generally reconcile to the outstanding balances.
I'd welcome some references to the statements or tables that led you to your belief. Even if I wanted to believe it I couldn't without some source material.
Here's all that the filings have to say about his compensation:
"Mr. Berman has served as Chief Financial Officer since January 2003 and as Principal Executive Officer since August
2006. During the fiscal years ended December 31, 2014 and 2015 and through September 30, 2016, Mr. Berman has received no cash compensation. Mr. Berman has not received any form of compensation as a result of our limited cash flow; Mr. Berman has agreed to accept stock and stock option awards as his compensation until such time the Company
has the necessary resources available to provide a traditional compensation plan."
This shows that Mr.Berman will take stock option awards when the company has the necessary resources. So that also tells me he is doing all he can to get this company profitable, and then the share price will take care of itself.
Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...
Continue Reading
KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...
Continue Reading
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...
Continue Reading
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
Top 5 Most Recently Viewed Articles
R Systems Acknowledged for Engineering Excellence R Systems International Limited, a leader in digital product engineering and technology solutions, has been recognized in the latest evaluation conducted by Everest Group. This prominent acknowledgment positions R Systems as a Major Contender in the ISV and Internet-specific SPES PEAK Matrix® Assessment for the year 2024....
Continue Reading
DA Davidson Affirms $300 Price Target for AppFolio Recently, DA Davidson reaffirmed its Buy rating for AppFolio (NASDAQ: APPF) and maintained a price target of $300. As a leading provider of cloud-based software solutions, AppFolio is recognized for its strategic growth initiatives. The firm highlighted the company's momentum ahead of its third-quarter earnings report and...
Continue Reading
Class Action Overview for West Pharmaceutical Services, Inc. Levi & Korsinsky, LLP informs all investors in West Pharmaceutical Services, Inc. about a significant class action securities lawsuit arising from claims of securities fraud against the company. This announcement serves as an important notice to those who hold shares of West Pharmaceutical Services, Inc. (NYSE:...
Continue Reading
Explore the Upcoming Investor Forum by Zelluna Zelluna (OSE: ZLNA), a trailblazer in the realm of allogeneic 'off the shelf' T Cell Receptor-based Natural Killer (TCR-NK) cells aimed at combating cancer, has announced an engaging Investor Science and Strategy Forum that offers a closer look at their innovative approaches. This notable event is set to take place in Oslo,...
Continue Reading
Understanding the Shift in Airline Operations As airlines adapt to changing economic conditions and demand patterns, many have begun scaling back their flight offerings to certain international markets. The situation is particularly pronounced with regards to flights to China, where reduced demand and rising operational costs have forced several airlines to reconsider...
Continue Reading